|
Volumn 251, Issue 9, 2013, Pages 2243-2245
|
Intravitreal bevacizumab for iris tumor metastasized from large cell neuroendocrine carcinoma of lung
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIGLAUCOMA AGENT;
BEVACIZUMAB;
ADULT;
CLINICAL ARTICLE;
CLINICAL FEATURE;
DISEASE ASSOCIATION;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG RESPONSE;
FOLLOW UP;
HUMAN;
HUMAN TISSUE;
INTRAOCULAR PRESSURE;
IRIS TUMOR;
LARGE CELL NEUROENDOCRINE CARCINOMA;
LETTER;
LUNG BIOPSY;
LUNG CARCINOMA;
MALE;
MEDICAL HISTORY;
METASTASIS;
OUTCOME ASSESSMENT;
PATIENT ASSESSMENT;
PRIORITY JOURNAL;
RETINA FLUORESCEIN ANGIOGRAPHY;
SECONDARY GLAUCOMA;
SLIT LAMP;
TUMOR VOLUME;
VISUAL ACUITY;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
CARCINOMA, NEUROENDOCRINE;
FLUORESCEIN ANGIOGRAPHY;
HUMANS;
INTRAOCULAR PRESSURE;
INTRAVITREAL INJECTIONS;
IRIS NEOPLASMS;
LUNG NEOPLASMS;
MALE;
MIDDLE AGED;
NEOVASCULARIZATION, PATHOLOGIC;
TREATMENT OUTCOME;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
EID: 84885602034
PISSN: 0721832X
EISSN: 1435702X
Source Type: Journal
DOI: 10.1007/s00417-012-2218-y Document Type: Letter |
Times cited : (12)
|
References (7)
|